Post coronavirus-disease-vaccination immune reconstitution inflammatory syndrome in tuberculosis treatment: a case report.

Post coronavirus-disease-vaccination immune reconstitution inflammatory syndrome in tuberculosis treatment: a case report.

Publication date: Mar 03, 2025

Tuberculosis immune reconstitution inflammatory syndrome is an uncommon condition caused by excessive immune response against Mycobacterium tuberculosis. We report on a case which may have been precipitated by coronavirus disease messenger ribonucleic acid vaccine booster. A 47-year old Indian man developed reactivation tuberculosis in the cervical lymph nodes in the setting of immune suppression caused by tumor necrosis factor inhibitor adalimumab. The symptoms improved with starting antituberculous therapy, but 5 days after receiving a coronavirus disease booster messenger ribonucleic acid vaccine, he had recurrence of severe constitutional symptoms. After a detailed evaluation, he was diagnosed with immune reconstitution inflammatory syndrome and was successfully treated with high-dose steroid therapy, which was weaned off over several weeks. Immune reconstitution inflammatory syndrome should be considered as a differential in patients who develop paradoxical worsening of symptoms with antitubercular therapy in the setting of immune reconstitution. Hyperactive immune response after infection or messenger ribonucleic acid vaccine booster may have contributed to the development of immune reconstitution inflammatory syndrome syndrome in this patient.

Concepts Keywords
Coronavirus Adalimumab
High Adalimumab
Therapy Adalimumab
Tuberculosisimmune Antitubercular Agents
Vaccination Antitubercular Agents
Case report
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Humans
Male
Middle Aged
mRNA COVID vaccination
Tuberculosis, Lymph Node

Semantics

Type Source Name
disease MESH immune reconstitution inflammatory syndrome
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH syndrome
disease IDO immune response
pathway KEGG Coronavirus disease
disease IDO ribonucleic acid
drug DRUGBANK Adalimumab
disease MESH recurrence
disease MESH infection
disease MESH COVID-19
disease MESH Tuberculosis Lymph Node

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *